Test cemiplimab plus chemo before treatment for head and neck cancer
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage III or IV head and neck squamous cell cancer that has not spread to distant organs (no metastasis) and you have not had chemo or radiation before
- You must be 18 or older and able to travel back for repeat dosing and follow-up visits
- You need a tumor or lymph node biopsy that the team can use for immune testing (before starting treatment)
- Your blood counts and organ tests must be high enough (for example: hemoglobin above 8, and key liver/kidney numbers not too high)
- You must be well enough to do daily activities (ECOG performance status 0–1) and have at least 12 weeks expected life span
- If you could become pregnant (or can cause pregnancy), you must use effective birth control during the study, and pregnancy tests must be negative at baseline and Day 1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests two immunotherapy drugs (cemiplimab and fianlimab) combined with standard chemotherapy and radiation for people with advanced head and neck cancer that cannot be removed by surgery. The goal is to see if this combination can improve outcomes by helping the immune system attack the cancer.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests giving a combination of two drugs (an immunotherapy drug called a PD-1 inhibitor and a targeted therapy called cetuximab) before surgery to shrink head and neck cancers. The goal is to see if this approach lowers the chance of the cancer coming back after surgery.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.